No headlines found.
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Globe Newswire (Mon, 5-Feb 7:00 AM ET)
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Achilles Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ACHL.
As of March 28, 2024, ACHL stock price climbed to $1.25 with 248,020 million shares trading.
ACHL has a beta of 0.85, meaning it tends to be less sensitive to market movements. ACHL has a correlation of 0.03 to the broad based SPY ETF.
ACHL has a market cap of $50.96 million. This is considered a Micro Cap stock.
ACHL has outperformed the market in the last year with a price return of +42.1% while the SPY ETF gained +33.6%. ACHL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +44.8% and +2.5%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
ACHL support price is $1.12 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHL stock will trade within this expected range on the day.